Clinical Transplantation Tolerance: A Myth No More, But ...

American Journal of Kidney Diseases

Volumn 54, Issue 6, 2009, Pages 1005-1011

  Azzi, Jamil ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELATACEPT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; SIPLIZUMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG WITHDRAWAL; GENE EXPRESSION PROFILING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKEMIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NEPHROLOGIST; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 70450223522     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.08.005     Document Type: Article

References (44)

1. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 4379 (1953) 603-606
2. Merrill J.P., Murray J.E., Harrison J.H., and Guild W.R. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc. 160 4 (1956) 277-282
3. Sayegh M.H., and Carpenter C.B. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med. 351 26 (2004) 2761-2766
4. Suthanthiran M. Transplantation tolerance: fooling Mother Nature. Proc Natl Acad Sci U S A 93 22 (1996) 12072-12075
5. Ansari M.J., and Sayegh M.H. The arduous road to achieving an immunosuppression-free state in kidney transplant recipients. Nat Clin Pract Nephrol. 3 9 (2007) 464-465
6. Strober S., Dhillon M., Schubert M., et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med. 321 1 (1989) 28-33
7. Sayegh M.H., Fine N.A., Smith J.L., Rennke H.G., Milford E.L., and Tilney N.L. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med. 114 11 (1991) 954-955
8. Spitzer T.R., Delmonico F., Tolkoff-Rubin N., et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 68 4 (1999) 480-484
9. Burlingham W.J., Grailer A.P., Fechner Jr. J.H., et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 59 8 (1995) 1147-1155
10. Sanchez-Fueyo A., and Strom T.B. Immunological tolerance and liver transplantation. J Hepatol. 41 5 (2004) 698-705
11. Mazariegos G.V., Reyes J., Marino I.R., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63 2 (1997) 243-249
12. Devlin J., Doherty D., Thomson L., et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27 4 (1998) 926-933
13. Takatsuki M., Uemoto S., Inomata Y., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72 3 (2001) 449-454
14. Koshiba T., Li Y., Takemura M., et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol. 17 2 (2007) 94-97
15. Mazariegos G.V., Sindhi R., Thomson A.W., and Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol. 17 2 (2007) 114-119
16. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 355 13 (2006) 1318-1330
17. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 6 9 (2006) 2121-2133
18. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 358 4 (2008) 353-361
19. Scandling J.D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 358 4 (2008) 362-368
20. Salama A.D., Remuzzi G., Harmon W.E., and Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 108 7 (2001) 943-948
21. Salama A.D., Womer K.L., and Sayegh M.H. Clinical transplantation tolerance: many rivers to cross. J Immunol. 178 9 (2007) 5419-5423
22. Najafian N., Albin M.J., and Newell K.A. How can we measure immunologic tolerance in humans?. J Am Soc Nephrol. 17 10 (2006) 2652-2663
23. + T cells in human kidney transplant recipients. J Am Soc Nephrol. 14 6 (2003) 1643-1651
24. VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest. 106 1 (2000) 145-155
25. + T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med. 199 7 (2004) 1017-1023
26. Li Y., Koshiba T., Yoshizawa A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 4 12 (2004) 2118-2125
27. Mazariegos G.V., Zahorchak A.F., Reyes J., et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant. 3 6 (2003) 689-696
28. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 17 2 (2003) 77-88
29. Brouard S., Mansfield E., Braud C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 104 39 (2007) 15448-15453
30. Martinez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 118 8 (2008) 2845-2857
31. Fathman C.G., Soares L., Chan S.M., and Utz P.J. An array of possibilities for the study of autoimmunity. Nature 435 7042 (2005) 605-611
32. Lakkis F.G., and Sayegh M.H. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol. 14 9 (2003) 2402-2410
33. Koehn B., Gangappa S., Miller J.D., Ahmed R., and Larsen C.P. Patients, pathogens, and protective immunity: the relevance of virus-induced alloreactivity in transplantation. J Immunol. 176 5 (2006) 2691-2696
34. Valujskikh A., Pantenburg B., and Heeger P.S. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant. 2 6 (2002) 501-509
35. Kirk A.D., Hale D.A., Mannon R.B., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 76 1 (2003) 120-129
36. Wadman M. London's disastrous drug trial has serious side effects for research. Nature 440 7083 (2006) 388-389
37. Neujahr D.C., Chen C., Huang X., et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol. 176 8 (2006) 4632-4639
38. Turgeon N.A., Iwakoshi N.N., Phillips N.E., et al. Viral infection abrogates CD8(+) T-cell deletion induced by costimulation blockade. J Surg Res. 93 1 (2000) 63-69
39. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant. 6 10 (2006) 2282-2291
40. Thornley T.B., Brehm M.A., Markees T.G., et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol. 176 3 (2006) 1561-1570
41. Kawai T., and Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 21 4 (2009) 317-337
42. + T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 25 5 (2006) 783-793
43. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 9158 (1999) 1083-1091
44. Sho M., Sandner S.E., Najafian N., et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg. 236 5 (2002) 667-675